Gilteritinib purchase channels and prices

Gilteritinib (Gilteritinib) is an oral small molecule targeted drug mainly used to treat specific types of acute myeloid leukemia (AML), especially those with FLT3 mutations. The drug is approved for use in adult patients after prior therapy, including those who are resistant to or have relapsed from other treatment options. Due to its specificity against FLT3 mutations, giritinib has shown good clinical efficacy in the treatment of such patients, thus providing patients with a new treatment option.

Regarding the purchase channels of giritinib, patients can usually purchase it through hospital pharmacies, outpatient clinics or pharmacies. In China, the original drug of giritinib is already on the market, but it has not yet been included in medical insurance, so the burden on patients is relatively heavy. The common specifications are 40mg, 21 tablets and 2 boards, and the price of each box is about more than 20,000 yuan. In addition, some patients choose to purchase the Hong Kong or European version of gilitinib from overseas. The Hong Kong version of the original drug can be sold for up to 90,000 yuan per box, while the version launched in Europe, with a specification of 40mg*84 tablets, may cost up to 210,000 yuan per box. These prices will be affected by exchange rate fluctuations, so when purchasing, it is recommended that patients consult relevant channels in advance to obtain the latest information.

In order to reduce the cost of treatment, some generic drugs of giritinib are currently on the market. These generic drugs are basically the same as the original drug in terms of ingredients and efficacy. For example, the generic version of giritinib produced by a pharmaceutical factory in Laos is 40mg*84 tablets, and the price per box is more than 2,000 yuan, which undoubtedly provides a feasible option for some patients with relatively difficult economic conditions. However, when using generic drugs, patients should carefully choose formal channels to ensure the quality and safety of the drugs.

Reference materials:https://en.wikipedia.org/wiki/Gilteritinib